化痰祛瘀法联合艾拉莫德治疗白塞综合征的临床效果

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (432 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod in treating Beh?觭et syndrome patients on the changes of inflammatory indices, clinical efficacy and safety. Methods From December 2015 to February 2017, 50 patients with Beh?觭et syndrome in Handan Hospital of Traditional Chinese Medicine were selected. They were divided into Chinese and Western medicine group 25 cases and Western medicine group 25 cases. Chinese and Western medicine group was given reduce phlegm and eliminate stasis decoction and Iguratimod Tablets, Western medicine group was given Iguratimod Tablets. Clinical efficacy, C reactive protein level, immunoglobulin A level, adverse reactions of medicine in the two groups were compared after 2 months′ treatment. Results After treatment, C reactive protein and immunoglobin A levels decreased than those before treatment (P < 0.01), the levels of C reactive protein and immunoglobulin A in the Chinese and Western medicine group were significantly lower than those in the western medicine group (P ＜ 0.05). The clinical efficacy of the Chinese and Western medicine group was higher than the Western medicine group (P < 0.05); and adverse reactions rate in the Chinese and Western medicine group was lower than Western medicine group (P < 0.05). Conclusion Therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod can reduce Behcet syndrome patients′ C reactive protein and immunoglobulin A levels, improve clinical efficacy.

Key words： Behcet syndrome Traditional Chinese medicine Therapeutic regimen of reduce phlegm and eliminate stasis Efficacy Iguratimod

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yong1 HU Cuiping2 CHANG Junying1 NIU Yanyun3 DAI Pu4 GU Zhanqing1

Cite this article:

WANG Yong1 HU Cuiping2 CHANG Junying1 NIU Yanyun3 DAI Pu4 GU Zhanqing1. Clinical effect of therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod in treating Beh?觭et syndrome[J]. 中国医药导报, 2018, 15(36): 95-98.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2018/V15/I36/95

[1] Hatemi G，Seyahi E，Fresko I，et al. Beh?觭et′s syndrome：a critical digest of the 2013-2014 literature [J]. Clin Exp Rheumato1，2014，32（4 Suppl 84）：S112-S122.
[2] Vaiopoulos AG，Sfikakis PP，Kanakis MA，et al. Gastrointestinal manifestations of Beh?觭et′s disease：advances in evaluation and management [J]. Clin Exp Rheumatol，2014， 32（4 Suppl 84）：S140-S148.
[3] 中华医学会风湿病学分会.白塞综合征诊治指南[J].中华风湿病学杂志，2003，7（12）：762-764.
[4] Davatchi F，Sadeghi Abdollahi B，Chams-Davatchi C，et al. The saga of diagnostic/classification criteria in Behcet′s disease [J]. Int J Rheum Dis，2015，18（6）：594-605.
[5] 周仲瑛.中医内科学[M].北京：中国中医药出版社，2011：467-468.
[6] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994：273.
[7] Emmi G，Silvestri E，Squatrito D，et al. Beh?觭et′s syndrome pathophysiology and potential therapeutic targets [J]. Intern Emerg Med，2014，9（3）：257-265.
[8] 葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2013：830-842.
[9] 郭衍秋，潘丽丽，万瑾，等.白塞病大血管病变的临床特点分析[J].中国医药，2017，12（5）：766-770.
[10] 李国铨，刘楠，郑顔萍.白塞综合征20例临床分析[J].海南医学，2016，27（21）：3552-3553.
[11] 宋星慧，任立敏.白塞综合征血管病变特点的临床分析[J].中华临床医师杂志：电子版，2013，7（7）：3150-3152.
[12] 秦准，赵昶，程颐，等.白塞病血管病变彩色多普勒超声特点分析[J].中国医药，2016，11（12）：1855-1858.
[13] Hisamatsu T，Naganuma M，Matsuoka K，et al. Diagnosis and management of intestinal Beh?觭et′s disease [J]. Clin J Gastro enterol，2014，25（7）：205-212.
[14] Vaccarino L，Triolo G，Accardo-Palombo A，et al. Pathological implications of Thl Th2 cytokine geneticvariants in Beh?觭et′s disease：Data from a pilot study in a Sicilian population [J]. Biochem Genet，2013，51（11/12）：967-975.
[15] 王梦涛，倪丹红，王晓元，等.艾拉莫德对类风湿关节炎患者CD3+T细胞IFN-γ及细胞因子IL-6调节作用的研究[J].中国地方病防治杂志，2016，31（12）：1345-1346.
[16] 孟德钎，潘文友，李鞠，等.甲氨蝶呤联合艾拉莫德治疗难治性类风湿关节炎的效果[J].中国医药导报，2016， 13（3）：137-141.
[17] 康成辰，刘昆仑，张立亭，等.张鸣鹤教授治疗白塞综合征中甘草的应用[J].四川中医，2014，32（4）：18-19.
[18] 夏惠文.高冬来副主任中医师治疗白塞综合征经验[J].中医研究，2014，27（4）：38-39.
[19] 侯学敏，王守儒.王守儒教授中西医结合治疗白塞综合征经验总结[J].中医临床研究，2015，1（2）：68-69.
[20] 成洁，董军胜.徐玲主任医师从脾胃论治白塞综合征的经验[J].陕西中医，2014，35（4）：477-478.
[21] 孙剑虹，徐串联，严宇仙.解毒化瘀通络方治疗白塞氏病的临床研究[J].中国中医药科技，2014，21（5）：488-490.
[22] 周倩，吴皓.半夏总生物碱抗炎作用研究[J].中药药理与临床，2006，22（34）：87-88.
[23] 梁学清，李丹丹，黄忠威.茯苓药理作用研究进展[J].河南科技大学学报：医学版，2012，30（2）：154-156.
[24] 杨志军，李初谊，郭胜，等.当归及不同配伍对环磷酰胺诱导的小鼠免疫器官、吞噬功能的影响[J].西部中医药，2013，26（4）：8-10.
[25] 胡荣，杨金荣，王斌，等.不同配伍桃仁对赤芍水煎液中芍药苷含量的影响[J].中药与临床，2013，4（1）：16-18.